Real-time enrollment status for this grade 2 idh1-mutant glioma clinical trial
Current Status
Recruiting
Checked: October 21, 2026 at 2:56 AM UTC
| NCT Number | NCT07703436 |
| Recruiting Status | Recruiting |
| Condition | Grade 2 IDH1-mutant Glioma |
| Phase | PHASE2 |
| Target Enrollment | 40 participants |
| Active Locations | 12 sites in the US |
| Sponsor | Nuvation Bio Inc. |
| Last Updated on CT.gov | October 20, 2026 (Yesterday) |
As of October 21, 2026: Clinical trial NCT07703436 is currently recruiting participants. This phase2 study for grade 2 idh1-mutant glioma is actively seeking new participants at 12 locations across the United States. The study is sponsored by Nuvation Bio Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07703436 is actively recruiting participants as of October 21, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 12 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07703436 was last updated Yesterday (October 20, 2026). HelloStudys verifies this status automatically.